Revium Rx. operates as a pre-clinical stage biopharmaceutical company focused on the development of nanoparticle-based therapies in the United States. The company develops lipid-based platforms for a variety of uses including antimicrobial resistance and solid tumors; specializes in infectious diseases, including antibiotic-resistant infections, solid tumors, and vaccination; and develops nano-liposomal particles (NLP) based pharmaceutical candidates. It also offers Nano-Mupirocin, a NLP-based formulation of potent antibiotic mupirocin. In addition, the company develops nanoparticles-based formulation of an angiotensin receptor blockers; novel adjunct for cancer therapies: and novel immunization based on liposomal protein-loaded technology. The company was formerly known as Revium Recovery Inc. and changed its name to Revium Rx. in December 2024. Revium Rx. was incorporated in 1997 and is headquartered in Herzliya, Israel.
Frequently asked questions
What sector does Revium Recovery Inc (RVRC) operate in?
Revium Recovery Inc belongs to the Healthcare sector and operates in the Health Information Services industry.
What is Revium Recovery Inc (RVRC) current stock price?
As of the latest data, Revium Recovery Inc stock price is $1.43, with a previous close of $1.43.
What is Revium Recovery Inc (RVRC) current market capitalization?
Revium Recovery Inc market cap is approximately 86.84 million.
What is Revium Recovery Inc (RVRC) Earnings Per Share (EPS)?
The trailing EPS is -$4.72.
What is Revium Recovery Inc (RVRC) EBITDA?
Revium Recovery Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -732.00.
Does Revium Recovery Inc (RVRC) pay dividends?
No. Revium Recovery Inc does not pay a dividend.
What is Revium Recovery Inc (RVRC) beta (volatility) score?
Revium Recovery Inc has a beta of -0.417, indicating lower volatility than the overall market.
